Synklino
Latest round
- Series A
Last raised
- Jun 2022
Total raised
- $31M
Investors
- 4
About Synklino
Founded in 2017 in Charlottenlund, Denmark, Synklino ApS focuses on combating cytomegalovirus (CMV) infections in transplant patients. The company was co-founded by Thomas Kledal, who has a history in the biotechnology sector.Synklino ApS is focused on developing innovative therapies designed to eradicate the risk of cytomegalovirus (CMV) infections in transplant patients. Their primary product, SYN002, aims to improve the outcomes and quality of life for organ transplant recipients by either treating the donor organ ex vivo before transplantation or addressing the infection in the recipient in vivo post-transplant. This dual approach targets the significant challenges posed by CMV, which can lead to severe complications, increased morbidity, and prolonged hospital stays for patients undergoing transplantation.In the most recent financial year of 2020, Synklino reported zero revenue. The company aims to enhance its product offerings and expand its market presence, specifically targeting healthcare institutions across Europe and North America. These initiatives are expected to strengthen its position in the transplantation ecosystem, facilitating better patient outcomes and addressing critical health challenges associated with CMV.
Who invested in Synklino
4 investors across 2 rounds
See all investors in Synklino
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Synklino
Who invested in Synklino?
Synklino has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Synklino raised?
Synklino has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Synklino last raise money?
Synklino's most recent round on record is a Series A, in Jun 2022.
What does Synklino do?
Founded in 2017 in Charlottenlund, Denmark, Synklino ApS focuses on combating cytomegalovirus (CMV) infections in transplant patients.
Where is Synklino headquartered?
Synklino is headquartered in Charlottenlund, Denmark.
Which VCs invest in companies like Synklino?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Synklino's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Synklino? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.